Meissa Vaccines, Inc.

18 articles with Meissa Vaccines, Inc.

• 

  Meissa's Intranasal COVID-19 Vaccine Shows Promise in Non-Human Primates

  7/19/2021

  Meissa’s intranasal vaccine for COVID-19 equals the protection afforded by existing vaccines in the same class of subjects after only a single dose, according to data presented this week at the American Society of Virology annual meeting.

• Meissa Vaccines Begins Study of RSV Vaccine Candidate in Seronegative Children

  6/30/2021

  Meissa Vaccines announced today the first seronegative participants have received MV-012-968, Meissa’s intranasal live attenuated RSV vaccine candidate, in a Phase 1c study in infants and young children.

• 

  Meissa’s Nasal COVID-19 Vaccine Uses Codon Deoptimization for Stronger Responses

  3/25/2021

  Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.

• Meissa Announces First Dosing in Phase 2 Study of Intranasal Live Attenuated Vaccine Candidate for RSV

  1/21/2021

  The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV)

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Meissa Vaccines Expands Leadership Team as Company Advances Intranasal RSV and COVID-19 Live Attenuated Vaccine Candidates

  10/14/2020

  Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William

• 

  Biopharma Update on the Novel Coronavirus: July 20

  7/20/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
• 

  Another COVID-19 Vaccine Joins the Race – This Time, it’s a Live, Weakened Virus

  7/20/2020

  Another COVID-19 vaccine candidate recently entered the races. The difference – this one is a live attenuated (weakened) virus expressing the coronavirus’s signature spike protein on its surface. And it’s delivered nasally, not a shot.

• Meissa Vaccines Provides a Pipeline Update on Vaccine Candidates for COVID-19 and RSV

  6/30/2020

  Meissa’s COVID-19 vaccine candidate, MV-014-210, is designed to be delivered as a single, intranasal, adjuvant-free dose, that is economical and can be rapidly scaled to supply global demands Preliminary clinical data show MV-012-968, the company’s vaccine candidate for respiratory syncytial virus, is heavily attenuated and induces a RSV-specific mucosal IgA response in the majority of healthy adult, seropositive recipients SOUTH SAN FRANCIS

• 

  BioSpace Movers & Shakers, June 26

  6/26/2020

  Biopharma and life sciences companies bolster their executive teams and board with these Movers & Shakers.

• Meissa Vaccines Appoints Robert Jordan, Ph.D., Vice President, Research and Development

  6/25/2020

  Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the company has appointed Robert Jordan, Ph.D., Vice President, Research and Development. Dr. Jordan has more than 20 years of virology research and antiviral drug development experience in both academia and industry. He was most recently Director, Virology at Vir Biotechnolo

• Meissa Vaccines Receives FDA Clearance of IND Application for a Phase 1 Clinical Trial of MV-012-968 for Respiratory Syncytial Virus

  12/5/2019

  Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application to proceed with a U.S. clinical trial of MV-012-968, an investigational vaccine for respiratory syncytial virus (RSV).

• Meissa Vaccines Closes $30 Million Financing to Advance RSV Vaccine into Clinical Trials

  9/26/2019

  Company uses proprietary synthetic biology and genetic engineering technologies to design improved vaccines for serious respiratory infections

• Meissa Vaccines Closes $3.4 Million Financing to Advance RSV Vaccine to Clinic

  3/27/2019

  The financing included numerous undisclosed individual investors and will be used to advance the company’s RSV vaccine candidate into clinical trials.

• Meissa Vaccines' Cofounder and CEO Dr. Martin Moore to Present at World Vaccine Congress

  3/28/2018

  Meissa Vaccines, a biotechnology company developing vaccines to prevent viral respiratory infections, announced that Martin Moore, Ph.D., co-founder and CEO of Meissa Vaccines, will present at World Vaccine Congress Washington 2018.

• Meissa Vaccines Announces Seed Round Investment From FundRx

  8/3/2017

• Meissa Vaccines Awarded $1.6M Fast Track SBIR Grant To Advance IND Preparations For RSV Vaccine Candidate

  7/12/2017

• Meissa Vaccines Announces Award Of NIH SBIR Grant To Support Development Of Multivalent Human Rhinovirus Vaccine Candidate

  5/10/2017